Abstract
Background:
The immunogenicity of mRNA COVID-19 vaccines has been reported as highly variable in patients with inborn errors of immunity (IEI).
Objective:
The aim of this study was to study memory CD4+ T-cell-mediated responses against the Spike (S) protein of SARS-CoV-2 along with CMV peptides in a large IEI group composed of mostly predominantly antibody-deficient (PAD) patients.
Patients and methods:
In vitro antigen-specific T-cell anti-S and -CMV responses after two doses of mRNA COVID-19 vaccines were assessed in peripheral blood from 114 patients with IEI and 38 healthcare healthy controls (HCHC). Stimulation index (SI) based on the percentages of CD4+ T lymphocytes with effector memory phenotype CD45RA−CD27− (TEM) was quantified by flow cytometry.
Results:
Patients with IEI overall, as well as the two main groups of PAD [i.e., common variable immunodeficiency (CVID) and isotype or functional antibody deficiencies (IOFD)], showed frequencies of responder individuals and median SI against SARS-CoV-2 comparable to HCHC. However, those IEI and CVID subgroups positive for anti-CMV T-cell immunity showed a significantly reduced response (SI) against S-peptides when compared to their IEI and CVID counterparts who were anti-CMV TEM negative. This effect of CMV stratification is independent of age in our patient group.
Conclusion:
CMV latency negatively impacted the CD4+ TEM population’s functionality regarding COVID-19 vaccination in patients with CVID. Our results in patients with IEI and previous similar findings in healthy populations highlight the fact that when assessing immune-specific responses, the inclusion of CMV monitoring is suitable, is worthwhile, and may potentially be extended to vaccinations against different pathogens to prevent human disease more accurately.
Introduction
SARS-CoV-2 has been the most recent infectious challenge worldwide, and huge efforts were made to combat the COVID-19 pandemic. SARS-CoV-2 vaccines received emergency approval and became the main effective measure to reduce the incidence of cases, hospitalizations, and mortality in the general population globally (, ).
When the clinical benefits of COVID-19 vaccines have been studied in patients with inborn errors of immunity (IEI) (formerly called primary immunodeficiencies), reduced inpatient and intensive care unit (ICU) admissions and mortality were also demonstrated in these higher-risk patients, although worse outcomes remain superior compared to the general population (–).
Regarding COVID-19 vaccines’ immunogenicity, very variable seroconversion rates, antibody titers, and T-cell responses have been detected across the different IEI categories so far (–), highlighting the huge IEI heterogeneity and pointing to the idea that cellular response may be more important than humoral response in such COVID-19-vaccinated patients.
Several conditions such as age, concomitant use of immunosuppressive medication, and infections and non-infectious related complications may also underlie some previous controversial results. Within the group of predominantly antibody deficiencies (PADs), very interesting studies in patients with common variable immunodeficiency (CVID) have demonstrated that the presence of autoimmune cytopenia, lymphoproliferative disorders, and granulomatous-lymphocytic interstitial lung disease can influence the immunogenicity of SARS-CoV-2 vaccines (, ).
The evaluation of specific T-cell responses after SARS-CoV-2 infection and vaccination in the context of IEI stands to reason given the critical role of T lymphocytes in the control and clearance of viral human diseases (, ). Moreover, in COVID-19, T-cell-mediated immunity confers a diverse and broadly reactive immune response to ancestral and emerging SARS-CoV-2 variants of concern (, ). As most patients with IEI suffer from PAD, T-cell immunity reflects their real ability to generate immune responses to COVID-19 vaccines much better than antibodies. In many of these PAD patients, the quantitation of anti-SARS-CoV-2 immunoglobulin G (IgG) may be overrepresented due to its presence in the immunoglobulin preparations used as replacement therapy, or underrepresented because of the hampered production of antigen-specific antibodies while they are not being treated with immunoglobulin replacement therapy (IgRT) ().
Cytomegalovirus (CMV) is not a new but, rather, a very old DNA pathogen belonging to the family Herpesviridae, which is considered a modulator of the immune system function, largely due to the induction of immunosenescence, memory inflation, and adaptation of the immune repertoire (–). In healthy CMV-seropositive individuals, a high proportion of the peripheral circulating T-cell pool is CMV-specific (), with expansion of effector-memory T cells and a marked decrease in naïve T-cell subsets (, ).
Human latent CMV infection has been linked to more severe outcomes of other infectious diseases due to a failure to control different viral infections (). Regarding COVID-19, worse clinical outcomes (–) and the development of long-COVID (, , ) have already been observed in CMV-seropositive individuals. Moreover, Aquino et al. found higher proportions of effector CD4+ T lymphocyte subsets in African populations—with a known superior prevalence of CMV (99% seropositive individuals)—when compared to Europeans, and suggested that these differences may affect immune responses to SARS-CoV-2 infection ().
The impact of latent CMV infection on SARS-CoV-2 T-cell immunity following COVID-19 vaccination was first described in 2024, in healthy Dutch adults (). This important work has demonstrated that adults aged 70 years or above showed decreased SARS-CoV-2-specific interferon-γ (IFN-γ) responses compared to younger age groups, but only in the CMV-seropositive cohorts (). On the other hand, no significant differences had been found previously in ChAdOx1 nCoV-19 vaccine-specific T-cell responses when healthy young adult volunteers (aged 18–55 years) were stratified by CMV serostatus (). In another cohort of healthy individuals, the longevity of memory—cellular or humoral—response after SARS-CoV-2 mRNA vaccination was not decreased in CMV-seropositive older adults (≥65 years) when compared to those who were seronegative ().
We recently reported on a patient with CD4+ lymphopenia who showed persistent and strong T-cell responses to CMV but an impaired ability to mount T-cell or antibody responses to SARS-CoV-2 throughout five immunizations (), which led us to consider CMV infection as a potential additional risk factor for a reduced immunogenicity of COVID-19 vaccines in other immunodeficient patients.
To the best of our knowledge, no reports have been published that investigate a relationship between previous exposure to CMV and vaccine-mediated T-cell immunity against SARS-CoV-2 in patients with IEI. Our aim was to assess T-cell responses to SARS-CoV-2 vaccination and also evaluate whether CMV latency could influence T-cell immunogenicity of mRNA COVID-19 vaccines in a large group of patients with IEI.
Patients and methods
Study groups
Our single-center cross-sectional observational study enrolled 114 patients with IEI belonging to the National Reference Unit for Immunodeficiency at the Gregorio Marañón University Hospital in Madrid (Spain). There were 69 women and 45 men, aged between 22 and 80 years [median (interquartile range): 54 (–) years]. Between February and September of 2021, 98 out of the 114 patients with IEI (86%) received two doses of the mRNA-1273 COVID-19 vaccine (Moderna, Cambridge, MA, USA) 28 days apart, and the remaining 16 patients (14%) received two doses of the BNT162b2 COVID-19 vaccine (Pfizer, New York, NY, USA) with an interval of 21 days. Peripheral blood samples for assessing immune responses to SARS-CoV-2 and CMV were collected with a median of 89 (72–120) days after the second dose of vaccination.
Most of the patients with IEI (103) were naïve to SARS-CoV-2 infection according to the clinical information regarding COVID-19 derived from their medical records throughout the close follow-up, which was performed in our Outpatient Clinical Unit and Day Hospital from the beginning of the pandemic. At the time of the study, only 11 patients were infected with SARS-CoV-2 before the administration of mRNA COVID-19 vaccine and just 1 patient was infected after the two vaccine doses but before the evaluation of immune response. Infection was documented by positive nasal swab SARS-CoV-2 polymerase chain reaction (PCR) tests in four patients and antigen rapid tests in three patients. In the remaining five patients, positive SARS-CoV-2 IgG serology was detected before vaccination. Although three out of these five patients were under IgRT, IgG anti-SARS-CoV-2 should not have been passively transferred by immunoglobulin substitution but produced by the patients, since the serum samples of the three of them were obtained before April 2021 and immunoglobulin products did not contain SARS-CoV-2-specific antibodies until late 2021 or early 2022 ().
A total of 38 healthcare workers were also included as healthy controls (HCHC). Thirty of them were women and eight were men, aged between 26 and 65 years [50 (–)]. Of the 38 healthcare workers, 34 (89%) were vaccinated with two doses of BNT162b2 vaccine and 4 (11%) received primary mRNA-1273 vaccination between January and July of 2021. Peripheral blood samples were collected within 118 to 226 (median, 158) days after primary vaccination. All HCHC individuals were naïve to SARS-CoV-2 infection as known by repeated negative results of PCR routinely assessed by the Division of Labour Risks Prevention of our Hospital.
No severe adverse side effects of the mRNA vaccines were detected in either group.
This study was carried out in accordance with the Declaration of Helsinki and approved by the Ethics Committee (IEI vac SARS-CoV-2) of the Gregorio Marañón University Hospital.
Evaluation of virus-specific CD4+ T-cell immunity: AIM assay
An activation-induced markers (AIM) assay was used to evaluate in vitro virus-specific CD4+ T-cell immunity by multicolor flow cytometry as described previously ().
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient and resuspended in a concentration of 10 × 106 cells/mL in TExMACS medium with stable glutamine (Miltenyi Biotec, Bergisch Galdbac, Germany) and supplemented with 10% fetal bovine serum. A total of 1 × 106 cells per well were plated in 96-well U-bottom plates (Corning Inc., New York, NY, USA) along with 1 μL of co-stimulatory monoclonal antibodies CD28/CD49d [clones L293/L25] for each condition. Under specific antigen conditions, 2 μL of peptide pool compounds of 15-mer peptides with 11-amino-acid overlap was included. In case of CMV, the peptide pool covered the complete sequence of the pp65 protein (Peptivator CMV pp65, premium grade, Miltenyi Biotec, Bergisch Galdbac, Germany). For SARS-CoV-2, it covered the original strain of spike protein (Peptivator SARS-CoV-2 Prot_S, Miltenyi Biotec, Bergisch Galdbac, Germany). As a positive condition, 4 μL of anti-human CD3/CD28/CD2 antibodies (ImmunoCult™ Human CD3/CD28/CD2 T cell Activator, STEMCELL Technologies, Vancouver, BC, Canada) was added. Negative control condition was supplemented with 2 µL of medium. Then, cells were incubated for 44–48 h at 37°C in a humidified atmosphere containing 5% CO2.
Following incubation, cells from each well were recollected separately in flow cytometry single tubes and washed with 1 mL of phosphate-buffered saline (PBS)/EDTA buffer. After that, the cells in every tube were stained with 20 μL of a commercial kit of CD4 T-cell activation (Act-T4 Cell (CYT-AT4C) antibody combination (BD Biosciences, San Jose, CA, USA) which contain a mix of monoclonal antibodies against CD3 PerCP-Cy5.5 [clone UCHT1] and CD4 FITC [clone RPA-T4]; and CD25 APC [clone M-A251] and OX40 (CD134) PE [clone 134-1] as AIM. Moreover, 1 μL of CD45RA APC-H7 [clone HI100] and 1 μL of CD27 PE-Cy7 [clone M-T271] monoclonal antibodies were included to identify effector memory subsets of CD4+ T cells. Additionally, 3 μL of PBS was added to every tube. All monoclonal antibodies were from BD Biosciences. Cells were incubated for 20 min at room temperature in the dark, washed again, and resuspended in 200 μL of PBS buffer. Finally, stained cells were acquired using a FACSLyric cytometer from BD Biosciences, and at least 100,000 lymphocytes were recorded per sample. Flow cytometry data were analyzed with BD FACSuite software version 1.5.
Gating strategy is shown in Supplementary Figure S1A. Lymphocytes were gated based on size and granularity characteristics. Then, CD4+ T cells were selected by CD3 and CD4 expression and further classified by surface differentiation markers CD45RA and CD27 into effector memory (TEM) helper T cells (CD3+CD4+CD45RA−CD27−). Cellular immune response was expressed as the stimulation index (SI) calculated by dividing the percentage of CD4+ TEM AIM+ cells [co-expressing OX40 (CD134) and CD25] in stimulation conditions by the percentage of CD4+ TEM AIM+ cells in negative control. SI ≥ 2 was considered positive (). Four representative examples are shown in Supplementary Figure S1B.
Statistics
GraphPad Prism version 10 (GraphPad Software, San Diego, CA) was used to perform statistical analysis and graphical representation of the data. Data normality was previously checked in all variables using the Kolmogorov–Smirnov test. Differences between number of responder individuals (categorical variables) were assessed using Fisher’s exact test and were expressed in frequency or percentage along with their corresponding 95% confidence intervals (CIs) calculated using the Wilson/Brown method. Differences between the SI of antigen-specific CD4+ T-cell responses (continuous variables) were compared by the non-parametric Mann–Whitney U test for non-paired samples and were reported as median and interquartile range (IQR = P25–P75) and 95% CIs. A multiple linear regression analysis was performed to evaluate the contribution of latent CMV infection (defined as the positive/negative T-cell response to CMV status) and the age (in years) as independent variables on the cellular quantitative response to SARS-CoV-2 as the dependent variable. In each statistical graph, horizontal bars represent the median and IQR values. p < 0.05 was considered significant (two-sided) and the significance is depicted with the p-value.
Results
Table 1 shows the classification of our IEI group according to the IUIS criteria (): 105 were categorized as PAD [48 had CVID, 52 had isotype chain or functional antibody deficiencies (IOFD), 3 had agammaglobulinemia, and 2 had hyper-IgM syndromes], 2 patients had diseases of immune dysregulation, 3 had combined immunodeficiencies (2 di George and 1 Good syndromes), 1 was diagnosed as having a phagocytic disorder, and 3 had complement deficiencies. As shown in Table 1, 60/114 patients with IEI were receiving periodic intravenous or subcutaneous IgRT.
Table 1
| Group | n | Median age (years) | Sex (male/female) | IgRT (iv/sc) | Vaccine (Moderna/Pfizer) | Median days since second dose to blood collection |
|---|---|---|---|---|---|---|
| Patients with IEI (overall) | 114 | 54 (n.s.) | 45/69 (*) | 42/18 | 98/16 | 89 |
| Predominantly antibody deficiency | 105 | 54 | 42/63 | 40/18 | 92/13 | 91 |
| • Common variable immunodeficiency | 48 | 52 | 20/28 | 26/17 | 44/4 | 86 |
| • Isotype, light chain, or functional deficiencies | 52 | 57 | 19/33 | 12/0 | 44/8 | 104 |
| • Agammaglobulinemia | 3 | 49 | 3/0 | 2/1 | 2/1 | 62 |
| • Hyper IgM syndromes | 2 | 56 | 0/2 | 0/0 | 2/0 | 54 |
| Combined immunodeficiencies syndromic features | 3 | 26 | 2/1 | 1/0 | 2/1 | 60 |
| Complement deficiencies | 3 | 50 | 1/2 | 0/0 | 1/2 | 89 |
| Diseases of immune dysregulation | 2 | 58 | 0/2 | 1/0 | 2/0 | 32 |
| Congenital defects of phagocytes | 1 | 62 | 0/1 | 0/0 | 1/0 | 97 |
| HCHC | 38 | 50 | 8/30 | – | 4/34 | 158 |
Characteristics of patients and healthy controls.
IgRT, immunoglobulin replacement therapy; iv, intravenous; sc, subcutaneous; IEI, inborn error of immunity; HCHC, healthcare healthy controls; n.s., not statistically significant. *p < 0.05.
No significant difference was found in the median age of our patients with IEI when compared to HCHC. Regarding sex, the proportion of female patients was significantly higher (p = 0.0492) in the HCHC group than in the group of patients with IEI.
Figure 1A shows that 79% (90 out of the 114 patients with IEI) had circulating CD4+ TEM reactive to SARS-CoV-2 S-peptides. This percentage of responder patients and the median SI after S-antigen stimulation from the entire IEI group were not statistically significant when compared to the frequency of 71% (27 out of 38) and the intensity of T-cell response found in the HCHC group. Among the 24 non-responder patients with IEI (21%) who lacked circulating SARS-CoV-2 S-specific CD4+ TEM, 91.6% belonged to the PAD group. In order to analyze the potential impact of demographic differences on SARS-CoV-2 T-cell responses, we stratified IEI or HCHC groups by sex, but no significant differences were found in either the proportion of responders or their SI median values (not shown). When those 100 PAD patients from our IEI group were further classified as CVID or IOFD (Figure 1A), statistically significant differences were neither found in the frequency and intensity of CD4+ T-cell responses to S-peptides when compared to HCHC, or when comparing these two PAD major subgroups between them (i.e., CVID vs. IOFD).
Figure 1
Regarding CMV in vitro responses, as shown in Figure 1B, anti-CMV CD4+ TEM were detected in 68 out of the total 114 IEI participants (60%). The comparison of this frequency with 79% (30/38) found in HCHC reached statistical significance (p = 0.049), and the median SI of 2.5 against CMV peptides from all patients with IEI was also significantly lower (p = 0.0032) than the median SI in HCHC controls, which was 3.7. Both CVID and IOFD subgroups also showed a statistically significant reduced intensity of the CMV-specific CD4+ TEM response when compared to the SI from the HCHC group (median SI, 2.5 vs. 3.7, p = 0.01 and 2.0 vs. 3.7, p = 0.0009, respectively).
Next, we stratified all IEI and HCHC individuals into CMV latently infected or non-infected groups, according to their in vitro CMV-specific T-cell reactivity (i.e., qualitative positive or negative anti-CMV CD4+ TEM). Although anti-CMV serology was tested in every patient and healthy control (not shown), we considered specific IgG uninformative since most PAD individuals weakly produce antibodies and/or they are under IgRT as reflected in Table 1. Figure 2 shows that although the CMV-infected IEI patients’ subgroup had a similar frequency of SARS-CoV-2 responders (78%, 53/68) to the subgroup of patients with IEI lacking circulating anti-CMV CD4+ TEM (80.4%, 37/46), a statistically significant lower intensity in their SARS-CoV-2 responses (median SI, 2.8 vs. 3.8, p = 0.0294) was observed. This significant difference was replicated between the CVID group of patients, when comparing the median SI of 2.8 after SARS-CoV-2 in vitro stimulation from anti-CMV CD4+ TEM positive patients with CVID with the median SI of 4.5 in the patients with CVID who were anti-CMV CD4+ TEM negative. Such difference was not found when stratifying patients with IOFD or the HCHC group by their anti-CMV CD4+ TEM status, or in the frequency of responders to SARS-CoV-2 (Figure 2).
Figure 2
To better delineate the contribution of CMV latent infection to impaired T-cell immunity against SARS-CoV-2, patients with IEI divided into two groups based on their T-cell reactivity to CMV were further stratified by age using the median age value (54 years old) of the entire IEI group. The patients with IEI with circulating anti-CMV CD4+ TEM (n = 68, mean age 56 ± 13.6 years) turned out to be significantly older (p < 0.005) than those who are anti-CMV CD4+ TEM negative (n = 46, 48 ± 13.1 years). Figure 3 shows no apparent effect of age on COVID-19 vaccination-induced SARS-CoV-2-specific CD4+ TEM response when our group of patients underwent this analysis (i.e., patients with IEI with or without circulating anti-CMV CD4+ TEM, re-stratified as younger or older than 54 years). As expected, the highest SARS-CoV-2 CD4+ TEM response was found in the subgroup of CMV non-infected younger patients, but it is significant only when compared to both the younger and older subgroups of CMV latently infected patients with IEI, and non-significant when compared to its CMV counterpart of non-infected and older patients.
Figure 3
Finally, we performed a multiple regression analysis to determine the effect of CMV status and age and investigated their confounding interactions following SARS-CoV-2 vaccination. Table 2 shows the results of the multivariant model, confirming that the significant reduction of in vitro specific CD4+ TEM response against SARS-CoV-2 within patients with latent CMV infection is independent of age in our COVID-19-vaccinated patients with IEI.
Table 2
| Variable | Estimate | Standard error | p-value |
|---|---|---|---|
| Intercept | 4.792 | 0.829 | <0.0001 |
| CMV | −1.032 | 0.451 | 0.024 |
| Age | −0.009 | 0.015 | 0.577 |
Linear regression model for SARS-CoV-2 T-cell responses after two doses of mRNA COVID-19 vaccination in all patients with IEI.
The dependent variable is the magnitude of TEM anti-SARS-CoV-2 response measured by the stimulation index. Independent variables are qualitative anti-CMV TEM response and age in years. A significance level of p < 0.05 was considered for all two-tailed tests.
Discussion
This study shows, for the first time, CD4+ T-cell immune responses against SARS-CoV-2 and CMV when tested simultaneously by using a single-cell, multicolor flow cytometry-based assay. The COVID-19 pandemic challenged many clinical and research immunology laboratories to implement diverse in vitro SARS-CoV-2 antigen-specific T-cell assays; an AIM platform enabled us to perform immunophenotyping and gating of responder memory T lymphocytes, which is considered highly sensitive and specific (–).
Although the utility of tests measuring CMV-specific T-cell immunity has not yet been established in IEI cohorts (), such laboratory assays are currently used for the clinical management of other immunocompromised patients (i.e., patients undergoing solid organ and hematopoietic precursor cell transplantation) (, ). In our study design, CMV peptides were included as a control for every laboratory assay () as well as a different viral stimulation for a better understanding of the CMV immune status of our patients with IEI (). This approach finally allowed us to study the impact of CMV infection on the T-cell immunogenicity of SARS-CoV-2 vaccination in our IEI group.
According to exhaustive reviews on humoral and T-cell immunity after two doses of SARS-CoV-2 vaccines, 30% to 87% of patients with IEI showed vaccine-specific T cells (–). Our results demonstrate that both the frequency of responder individuals (75%–83%) and the intensity of SARS-CoV-2-specific responses were similar in all patients with IEI or IEI categories defined by the IUIS and the healthy control group, consistent with data previously reported in other IEI and CVID cohorts of patients, even when they were assessed by different in vitro methods and vaccine dosages (–). Since the literature regarding cellular response to COVID-19 vaccines in patients with IEI is conflicting, our results are in disagreement with the findings of other authors who have reported a declined SARS-CoV-2-specific T-cell response compared to healthy individuals (, , , , ). Lower anti-SARS-CoV-2 CD4+ T-cell memory responses correlate with the lack of generation of IgG-specific antibodies in patients with CVID (, ). CD8+ T cells are critical for viral control (, ), and a very recent study involving healthy subjects also determines a positive relationship between anti-SARS-CoV-2 AIM CD8+ T cells and neutralizing antibody responses (), although CD8+ memory T-cell responses were not measurable even in the healthy control group of a previous study (). Different vaccination strategies, time to evaluation, and methods to quantitate immunogenicity plus the heterogeneous nature of patients with IEI included in these studies may underlie such contradictory findings. Standardized methodologies to assess T cellular responses would be needed in order to reach clearer conclusions on the immune status against SARS-CoV-2 in vaccinated patients with IEI, and it may be advantageous to include CD8+ T-cell responses in future designs.
In contrast to SARS-CoV-2 stimulation, we found a significant decrease in the intensity of CMV-specific T-cell responses in the total group of patients with IEI and in our two major subgroups of PAD patients (CVID and IOFD) when compared to healthy donors. Despite CVID being considered a typical PAD, it is known that a subset of patients with CVID display additional features of cellular immunodeficiency, with viral infection as a clinically relevant hallmark (, ), which could explain the lower T-cell responses to latent CMV infection in our patients. The reasons why our patients with IEI could have a lower prevalence of CMV infection than our HCHC group remain unclear. HCHC with a median age of 50 years are not significantly younger than the entire IEI group with a median age of 54 years (not shown). Since a second peak in middle age of CMV primoinfection has been noted in developed countries (), this peak might be reduced in our patients with IEI—mostly PAD—by some protection associated to IgRT or because of a decreased exposure in their IEI context when compared with healthcare workers.
Our results agree with the study of Hetemaki et al., who found impaired anti-CMV cellular functions by ELISpot in APECED (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy) patients with IEI compared to healthy controls (), and disagree with the findings of other authors who reported non-significant differences between the CD4+ T-cell responses of patients with CVID and healthy individuals as measured by IFN-γ secretion after CMV peptide stimulation (). However, Raeiszadeh et al. described increased CMV-specific activated and terminally differentiated CD8+ T cells with functional responses (). Since most patients in clinical immunology units have PAD, implementing the evaluation of cellular responses to CMV could help one to know the functionality of their T cells, as well as their susceptibility to CMV infection, or even whether they are reactivating CMV as detected by an increase in the T-cell response ().
One of our patients with IEI showed undetectable SARS-CoV-2 CD4+ T-cell responses in vitro and repeated specific antibody generation failure, which were strikingly discordant with the strong CMV cellular and humoral responses observed throughout his entire follow-up, including five doses of mRNA COVID-19 vaccines (). Of note, this particular patient has shown S-specific T-cell response after the sixth SARS-CoV-2 vaccine immunization (not shown) while remaining naïve to natural SARS-CoV-2 infection (by means of repeatedly negative home nasal swab antigen tests when he was suspected of having COVID-19). This case of ours, along with the impact of CMV after primary COVID-19 vaccination recently reported within the oldest healthy adults from a Dutch general population cohort, prompted us to study a possible association between CMV status and SARS-CoV-2 Spike-specific CD4+ T-cell immunogenicity in our entire cohort of patients with IEI. Overall, our results support the idea that variation in SARS-CoV-2 T-cell immune responses could be due to CMV infection.
How CMV infection might compromise the quality of immune protection after vaccination remains poorly understood. CMV-induced changes in the T-cell repertoire (), the significant driving of major expansions of specific effector and memory T cells to keep this β-herpes virus in latency, and the increased expression of senescence-associated markers (, , ) could underlie the worse quality of memory CD4+ T-cell responses to neoantigens from SARS-CoV-2 observed in the entire group of patients with IEI or in patients with CVID. The lack of impact of CMV latency in our group of patients with IOFD could be related to the active replication of CMV infection. CMV viremia was not tested in our patients, but it has been recently reported to be positive and related to cellular dysregulation in 16% of patients with CVID (, ) and in none of the patients with IOFD included in a previous study (). Our findings are in line with the fascinating study of Bowyer et al. (), who also had the opportunity to evaluate the impact of CMV on vaccine-induced immune responses to another neoantigen—the Ebola glycoprotein—and found that the higher CMV seroprevalence in Africa was associated with reduced vaccine-induced responses to Ebola. There are other previous demonstrations of the ability of CMV to reduce immune system responses to more common immunizations, mainly derived from studies after influenza (, ) and tick-borne encephalitis vaccines (). Controversial results have been reported in these investigations (, , , ), and a meta-analysis studying the influence of CMV serostatus on the humoral response to influenza vaccination has concluded with insufficient evidence ().
The passage of time also has an inevitable role in immunosenescence, and age is another risk factor for poor cellular responses induced after vaccination (, ). There is also an increasing agreement that the impact of CMV can differ depending on the age of the host, with worse immune responses in older than in younger individuals (). Therefore, we took into consideration age-associated immunosenescence as potentially responsible for a skewed repertoire with less effector T-cell functions (, , ). In our IEI group, multivariant analysis did not show a significant effect of age on the T-cell response to SARS-CoV-2 following two vaccination doses. Since 50% of our patients were under the age of 54 years, we hypothesize that their immunodeficient condition could be adding to CMV status with an equivalent effect as the age.
The cross-sectional design of the present study does not allow causal inferences or longitudinal assessment. Unfortunately, we were unable to compare in vitro antigen-specific CD4+ T-cell responses in those subgroups of non-PAD IEI made up of a small number of patients. For the same reason, some observations in our study may also be limited by the low representation of very young or elderly individuals. Further studies in different cohorts devoted to younger and older patients and healthy donors are needed in order to validate the data presented here; it would also be interesting to analyze the long-term impact of CMV infection on immunogenicity to subsequent COVID-19 immunizations and hybrid immunity.
In conclusion, here we have demonstrated the negative impact of latent CMV infection on immunogenicity after two doses of mRNA SARS-CoV-2 vaccines in selected forms of PAD patients like CVID. We emphasize the importance of understanding the immune status of CMV and tailoring booster strategies for vaccine-preventable diseases by using novel T-cell functional assays, not only for the vaccines mentioned above but also for other vaccines (i.e., herpes zoster vaccination), in immunocompromised patients.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Comité de ética de la investigación con medicamentos Hospital General Universitario Gregorio Marañón. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
Author contributions
TA-C: Formal Analysis, Investigation, Methodology, Validation, Writing – original draft. RA: Investigation, Writing – review & editing. HB-M: Investigation, Writing – review & editing. LB-G: Methodology, Writing – review & editing. PS-M: Writing – review & editing. MM-L: Investigation, Writing – review & editing. JG-H: Conceptualization, Formal Analysis, Investigation, Supervision, Writing – original draft.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
We wish to acknowledge Jane Kinnear for her invaluable help, the excellence of nurses Esperanza Ruiz de León and Maria Ángeles Escobar Palazón, JM Bellón for his statistical support and the patients and healthcare healthy controls for their continued collaboration in this work. We thank RETAR-A-COVID-CM, grant S2022/BMD-7274 to P.S-M for the payment of publishing charges.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1659259/full#supplementary-material
Supplementary Figure 1Identification of antigen-specific CD4+ T lymphocytes following two doses of mRNA-COVID-19 vaccination through AIM assays. (A) Gating strategy of effector memory CD4+ T-cells (TEM) in a patient with inborn error of immunity (IEI) and a healthy control. The lymphocyte gate was defined based on forward scatter (FSC) and side scatter (SSC) characteristics of PMBC. Then, CD3+CD4+ helper T-cells were selected, and CD4+ TEM cells were identified by the absence of CD45RA and CD27 surface expression. (B) Illustrative density plots showing the TEM responses to CMV pp65 and spike-SARS-CoV-2 peptides in two representative patients with IEI (P-1 and P-2) and healthy controls (HCHC-1 and HCHC-2).
Abbreviations
AIM, Activation-induced markers; APECED, Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; TEM, CD4+ T lymphocytes with effector memory phenotype CD45RA−CD27−; CVID, Common variable immunodeficiency; CMV, Cytomegalovirus; HCHC, Healthcare healthy controls; IgRT, Immunoglobulin replacement therapy; IEI, Inborn errors of immunity; IOFD, Isotype or functional antibody deficiencies; PBMCs, Peripheral blood mononuclear cells; PAD, Predominantly antibody deficiencies; S, Spike-protein; SI, Stimulation index
References
1
SinghPAnandARanaSKumarAGoelPKumarSet al. Impact of COVID-19 vaccination: a global perspective. Front Public Health. (2024) 11:1272961. doi: 10.3389/fpubh.2023.1272961
2
WatsonOJBarnsleyGToorJHoganABWinskillPGhaniAC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. (2022) 22:1293–302. doi: 10.1016/S1473-3099(22)00320-6
3
EvansRADubeSLuYYatesMArnetorpSBarnesEet al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. (2023) 35:100747. doi: 10.1016/j.lanepe.2023.100747
4
LindahlHKahnFNilsdotter-AugustinssonÅFredriksonMHedbergPMöllerIKet al. Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population. J Allergy Clin Immunol. (2025) 155:387–397.e6. doi: 10.1016/j.jaci.2024.10.013
5
ShieldsAMTadrosSAl-HakimANellJMLinMMNChanMet al. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.984376
6
Chang-RableyEvan ZelmMCRicottaEEEdwardsESJ. An overview of the strategies to boost SARS-coV-2-specific immunity in people with inborn errors of immunity. Vaccines (Basel). (2024) 12:675. doi: 10.3390/vaccines12060675
7
CusaGSardellaGGarziGFirinuDMilitoC. SARS-CoV-2 vaccination in primary antibody deficiencies: an overview on efficacy, immunogenicity, durability of immune response and safety. Curr Opin Allergy Clin Immunol. (2024) 24:37–43. doi: 10.1097/ACI.0000000000000955
8
ParisR. SARS-coV-2 infection and response to COVID-19 vaccination in patients with primary immunodeficiencies. J Infect Dis. (2023) 228:S24–33. doi: 10.1093/infdis/jiad145
9
OlivieriGAmodioDMannoECSantilliVCotugnoNPalmaP. Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies. Vaccine. (2025) 51:126853. doi: 10.1016/j.vaccine.2025.126853
10
van LeeuwenLPMGeurtsvanKesselCHEllerbroekPMde BreeGJPotjewijdJRutgersAet al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol. (2022) 149:1949–57. doi: 10.1016/j.jaci.2022.04.002
11
Arroyo-SánchezDCabrera-MaranteOLaguna-GoyaRAlmendro-VázquezPCarreteroOGil-EtayoFJet al. Immunogenicity of anti-SARS-coV-2 vaccines in common variable immunodeficiency. J Clin Immunol. (2022) 42:240–52. doi: 10.1007/s10875-021-01174-5
12
JarjourNNMasopustDJamesonSC. T cell memory: understanding COVID-19. Immunity. (2021) 54:14–8. doi: 10.1016/j.immuni.2020.12.009
13
TanATLinsterMTanCWLe BertNChiaWNKunasegaranKet al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. (2021) 34:108728. doi: 10.1016/j.celrep.2021.108728
14
GaoYCaiCGrifoniAMüllerTRNiesslJOlofssonAet al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med. (2022) 28:472–6. doi: 10.1038/s41591-022-01700-x
15
TarkeACoelhoCHZhangZDanJMYuEDMethotNet al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. (2022) 185:847–59. doi: 10.1016/j.cell.2022.01.015
16
IJspeertHEdwardsESJO’HehirREDalmVASHvan ZelmMC. Update on inborn errors of immunity. J Allergy Clin Immunol. (2025) 155:740–51. doi: 10.1016/j.jaci.2024.12.1075
17
BanoAPeraAAlmoukayedAClarkeTHSKirmaniSDaviesKAet al. CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Res. (2019) 8F1000 Faculty Rev-327. doi: 10.12688/f1000research
18
ChidrawarSKhanNWeiWMcLarnonASmithNNayakLet al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol. (2009) 155:423–32. doi: 10.1111/j.1365-2249.2008.03785.x
19
KlenermanPOxeniusA. T cell responses to cytomegalovirus. Nat Rev Immunol. (2016) 16:367–77. doi: 10.1038/nri.2016.38
20
MüllerLDi BenedettoS. Immunosenescence and cytomegalovirus: exploring their connection in the context of aging, health, and disease. Int J Mol Sci. (2024) 25:753. doi: 10.3390/ijms25020753
21
PourgheysariBKhanNBestDBrutonRNayakLMossPAH. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol. (2007) 81:7759–65. doi: 10.1128/JVI.01262-06
22
WallerECPDayESissonsJGPWillsMR. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol. (2008) 197:83–96. doi: 10.1007/s00430-008-0082-5
23
SylwesterAWMitchellBLEdgarJBTaorminaCPelteCRuchtiFet al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. (2005) 202:673–85. doi: 10.1084/jem.20050882
24
PardieckINBeyrendGRedekerAArensR. Cytomegalovirus infection and progressive differentiation of effector-memory T cells. F1000Res. (2018) 7F1000 Faculty Rev-1554. doi: 10.12688/f1000research
25
WeinbergerBLazuardiLWeiskirchnerIKellerMNeunerCFischerKHet al. Healthy aging and latent infection with CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly. Hum Immunol. (2007) 68:86–90. doi: 10.1016/j.humimm.2006.10.019
26
AlanioCVermaAMathewDGoumaSLiangGDunnTet al. Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization. J Infect Dis. (2022) 226:463–73. doi: 10.1093/infdis/jiac020
27
GattoIBiagioniEColorettiIFarinelliCAvoniCCaciagliVet al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. (2022) 48:706–13. doi: 10.1007/s00134-022-06716-y
28
WeberSKehlVErberJWagnerKIJetzlspergerAMBurrellTet al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PloS One. (2022) 17:e0268530. doi: 10.1371/journal.pone.0268530
29
GáspárZSzabóBGCeglédiALakatosB. Human herpesvirus reactivation and its potential role in the pathogenesis of post-acute sequelae of SARS-CoV-2 infection. GeroScience. (2025) 47(1):167–87. doi: 10.1007/s11357-024-01323-9
30
MüllerLDi BenedettoS. How immunosenescence and inflammaging may contribute to hyperinflammatory syndrome in COVID-19. Int J Mol Sci. (2021) 22:12539. doi: 10.3390/ijms222212539
31
AquinoYBisiauxALiZO’NeillMMendoza-RevillaJMerklingSHet al. Dissecting human population variation in single-cell responses to SARS-CoV-2. Nature. (2023) 621:120–8. doi: 10.1038/s41586-023-06422-9
32
BrummelmanJSuárez-HernándezSde RondLBogaard-van MaurikMMolenaarPvan WijlenEet al. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status. Front Immunol. (2024) 15:1392477. doi: 10.3389/fimmu.2024.1392477
33
SharpeHRProvineNMBowyerGSMoreira FolegattiPBelij-RammerstorferSFlaxmanAet al. CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight. (2022) 7(6):e154187. doi: 10.1172/jci.insight.154187
34
BreznikJAHuynhAZhangABilaverLBhaktaHStaceyHDet al. Cytomegalovirus seropositivity in older adults changes the T cell repertoire but does not prevent antibody or cellular responses to SARS-coV-2 vaccination. J Immunol. (2022) 209:1892–905. doi: 10.4049/jimmunol.2200369
35
Alba-CanoTFernández-CruzEAlonsoRMuñoz-GómezSPérez de DiegoRGarcía MartínezEet al. Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4+ T-Cell Lymphopenia but Preserved Responses to CMV. Vaccines (Basel). (2024) 12:386. doi: 10.3390/vaccines12040386
36
UnninayarDFalconeELChapdelaineHVinhDCTopKADerfalviBet al. Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections. Front Immunol. (2024) 15:1501908. doi: 10.3389/fimmu.2024.1501908
37
PoliMCAksentijevichIBousfihaAACunningham-RundlesCHambletonSKleinCet al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J Hum Immunity. (2025) 1:e20250003. doi: 10.70962/jhi.20250003
38
ZaundersJJMunierMLSeddikiNPettSIpSBaileyMet al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol. (2009) 183:2827–36. doi: 10.4049/jimmunol.0803548
39
TormoNGiménezEMartínez-NavarroMAlbertENavalpotroDTorresIet al. Performance comparison of a flow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2 test for detection and quantification of SARS-CoV-2-Spike-reactive-IFN-γ-producing T cells after COVID-19 vaccination. Eur J Clin Microbiol Infect Dis. (2022) 41:657–62. doi: 10.1007/s10096-022-04422-7
40
BowyerGRamplingTPowlsonJMorterRWrightDHillAVSet al. Activation-induced markers detect vaccine-specific CD4+ T cell responses not measured by assays conventionally used in clinical trials. Vaccines (Basel). (2018) 6:50. doi: 10.3390/vaccines6030050
41
GodsellJChanSSladeCBryantVDouglassJASasadeuszJet al. Cytomegalovirus in primary immunodeficiency. Curr Opin Infect Dis. (2021) 34:663–71. doi: 10.1097/QCO.0000000000000797
42
RogersRSahariaKChandrokarAWeissZFVieiraKKooSet al. Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events. BMC Infect Dis. (2020) 20:58. doi: 10.1186/s12879-020-4787-4
43
RezahosseiniOMøllerDLKnudsenADSørensenSSPerchMGustafssonFet al. Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: A systematic review. Front Immunol. (2020) 11:567715. doi: 10.3389/fimmu.2020.567715
44
GrifoniAWeiskopfDRamirezSIMateusJDanJMModerbacherCRet al. Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. (2020) 181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015
45
Lopes da SilvaVGSchmitzGJHSullivanKEBarbateJde Haro AzinarMIArandaCSet al. Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls. Front Immunol. (2025) 16:1538453. doi: 10.3389/fimmu.2025.1538453
46
AmodioDRuggieroASgrullettiMPighiCCotugnoNMedriCet al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. (2021) 12:727850. doi: 10.3389/fimmu.2021.727850
47
BloomfieldMParackovaZHanzlikovaJLastovickaJSedivaA. Immunogenicity and safety of COVID-19 mRNA vaccine in STAT1 GOF patients. J Clin Immunol. (2022) 42:266–9. doi: 10.1007/s10875-021-01163-8
48
ErraLUriarteIColadoAPaoliniMVSeminarioGFernándezJBet al. COVID-19 vaccination responses with different vaccine platforms in patients with inborn errors of immunity. J Clin Immunol. (2023) 43:271–85. doi: 10.1007/s10875-022-01382-7
49
GöschlLMrakDGrabmeier-PfistershammerKStiasnyKHaslacherHSchneiderLet al. Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency. Front Immunol. (2022) 13:974987. doi: 10.3389/fimmu.2022.974987
50
LinFJDossAMADavis-AdamsHGAdamsLJHansonCHVanBlarganLAet al. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. Front Immunol. (2022) 13:1033770. doi: 10.3389/fimmu.2022.1033770
51
LucaneZSlisereBOzolaLRotsDPapirteSVilneBet al. Long-Term Immunological Memory of SARS-CoV-2 Is Present in Patients with Primary Antibody Deficiencies for up to a Year after Vaccination. Vaccines (Basel). (2023) 11:354. doi: 10.3390/vaccines11020354
52
ShieldsAMFaustiniSEHillHJAl-TaeiSTannerCAshfordFet al. SARS-coV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. J Clin Immunol. (2022) 42:923–34. doi: 10.1007/s10875-022-01231-7
53
La CivitaEZannellaCBrusaSRomanoPSchettinoESalemiFet al. BNT162b2 elicited an efficient cell-mediated response against SARS-coV-2 in kidney transplant recipients and common variable immunodeficiency patients. Viruses. (2023) 15:1659. doi: 10.3390/v15081659
54
HaginDFreundTNavonMHalperinTAdirDMaromRet al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. (2021) 148:739–49. doi: 10.1016/j.jaci.2021.05.029
55
AntolíARocamora-BlanchGFramilMMas-BoschVNavarroSBermudezCet al. Evaluation of humoral and cellular immune responses to the SARS-coV-2 vaccine in patients with common variable immunodeficiency phenotype and patient receiving B-cell depletion therapy. Front Immunol. (2022) 13:895209/full. doi: 10.3389/fimmu.2022.895209/full
56
SauerweinKMTGeierCBStembergerRFAkyamanHIllesPFischerMBet al. Antigen-specific CD4+ T-cell activation in primary antibody deficiency after BNT162b2 mRNA COVID-19 vaccination. Front Immunol. (2022) 13:827048. doi: 10.3389/fimmu.2022.827048
57
PulvirentiFDi CeccaSSinibaldiMPiano MortariETerreriSAlbanoCet al. T-cell defects associated to lack of spike-specific antibodies after BNT162b2 full immunization followed by a booster dose in patients with common variable immune deficiencies. Cells. (2022) 11:1918. doi: 10.3390/cells11121918
58
TongSLitwinSMEpelESLinJDrurySSHechtFMet al. COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response. Vaccine. (2025) 61:127420. doi: 10.1016/j.vaccine.2025.127420
59
Cunningham-RundlesC. Common variable immune deficiency: dissection of the variable. Immunol Rev. (2019) 287:145. doi: 10.1111/imr.12728
60
BonillaFABarlanIChapelHCosta-CarvalhoBTCunningham-RundlesCde la MorenaMTet al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol In practice. (2015) 4:38. doi: 10.1016/j.jaip.2015.07.025
61
HetemäkiIHeikkiläNPetersonPKekäläinenEWillcoxNAnetteSBWet al. Decreased T-cell response against latent cytomegalovirus infection does not correlate with anti-IFN autoantibodies in patients with APECED. APMIS. (2024) 132:881–7. doi: 10.1111/apm.13458
62
RaeiszadehMKopycinskiJPastonSJDissTLowdellMHardyGADet al. The T cell response to persistent herpes virus infections in common variable immunodeficiency. Clin Exp Immunol. (2006) 146:234–42. doi: 10.1111/j.1365-2249.2006.03209.x
63
DunnHSHaneyDJGhanekarSAStepick-BiekPLewisDBMaeckerHT. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis. (2002) 186:15–22. doi: 10.1086/341079
64
MarashiSMRaeiszadehMEnrightVTahamiFWorkmanSCheeRet al. Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. J Allergy Clin Immunol. (2012) 129:1349–1356.e3. doi: 10.1016/j.jaci.2012.02.011
65
MarriLContiniPIvaldiFSchiaviCMagnaniOVassalloCet al. Evaluation of frequency of CMV replication and disease complications reveals new cellular defects and a time dependent pattern in CVID patients. J Clin Immunol. (2024) 44:142. doi: 10.1007/s10875-024-01744-3
66
BezPSantangeliEGoldackerSSalzerUWarnatzK. Expansion of CD57+ CD8 T cells in common variable immunodeficiency with hepatopathy and CMV infection. Front Immunol. (2025) 16:1577934. doi: 10.3389/fimmu.2025.1577934
67
BowyerGSharpeHVenkatramanNNdiayePBWadeDBrennerNet al. Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. J Exp Med. (2020) 217:e20200004. doi: 10.1084/jem.20200004
68
DerhovanessianETheetenHHähnelKVan DammePCoolsNPawelecG. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. (2013) 31:685–90. doi: 10.1016/j.vaccine.2012.11.041
69
DerhovanessianEMaierABHähnelKMcElhaneyJESlagboomEPPawelecG. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol. (2014) 193:3624–31. doi: 10.4049/jimmunol.1303361
70
ZlamyMWürznerRHolzmannHBrandstätterAJellerVZimmerhacklLBet al. Antibody dynamics after tick-borne encephalitis and measles-mumps-rubella vaccination in children post early thymectomy. Vaccine. (2010) 28:8053–60. doi: 10.1016/j.vaccine.2010.10.002
71
MeraniSPawelecGKuchelGAMcElhaneyJE. Impact of aging and cytomegalovirus on immunological response to influenza vaccination and infection. Front Immunol. (2017) 8:784. doi: 10.3389/fimmu.2017.00784
72
den ElzenWPJVossenACMTCoolsHJMWestendorpRGJKroesACMGusseklooJ. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine. (2011) 29:4869–74. doi: 10.1016/j.vaccine.2011.03.086
73
van den BergSPHWarminkKBorghansJAMKnolMJvan BaarleD. Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis. Med Microbiol Immunol. (2019) 208:305–21. doi: 10.1007/s00430-019-00602-z
74
FuentesEFuentesMAlarcónMPalomoI. Immune system dysfunction in the elderly. Acad Bras Cienc. (2017) 89:285–99. doi: 10.1590/0001-3765201720160487
75
KadambariSKlenermanPPollardAJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev Med Virology. (2020) 30:e2144. doi: 10.1002/rmv.2144
76
SansoniPVescoviniRFagnoniFBiasiniCZanniFZanlariLet al. The immune system in extreme longevity. Exp Gerontology. (2008) 43:61–5. doi: 10.1016/j.exger.2007.06.008
77
GoronzyJJWeyandCM. Successful and maladaptive T cell aging. Immunity. (2017) 46:364–78. doi: 10.1016/j.immuni.2017.03.010
Summary
Keywords
COVID-19, SARS-CoV-2, mRNA vaccines, inborn errors of immunity, IEI, common variable immunodeficiency, CVID, CMV
Citation
Alba-Cano T, Alonso R, Balastegui-Martín H, Bravo-Gallego LY, Sánchez-Mateos P, Martín-López M and Gil-Herrera J (2025) Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients. Front. Immunol. 16:1659259. doi: 10.3389/fimmu.2025.1659259
Received
03 July 2025
Accepted
08 September 2025
Published
30 September 2025
Volume
16 - 2025
Edited by
Guzide Aksu, Ege University, Türkiye
Reviewed by
Emily S.J. Edwards, Monash University, Australia
Vitor Gabriel Lopes da Silva, Federal University of São Paulo, Brazil
Updates
Copyright
© 2025 Alba-Cano, Alonso, Balastegui-Martín, Bravo-Gallego, Sánchez-Mateos, Martín-López and Gil-Herrera.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Juana Gil-Herrera, juanagil@ucm.es
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.